NEW YORK (GenomeWeb News) – Japanese pharmaceutical firm Sanwa Kagaku Kenkyusho has licensed VistaGen Therapeutics’ embryonic stem cell-based assay systems for use in diabetes drug development, VistaGen said today.
Under the terms of the license agreement, Sanwa will use three of VistaGen’s customized beta-islet differentiation assay systems to identify and screen new small-molecule drug candidates to treat type 1 and type 2 diabetes.
The companies co-developed the assays under an ongoing joint research and development agreement that used VistaGen’s ES Cell technology and bioinformatics databases to identify biomolecules for cell differentiation and insulin production.
VistaGen also has the right to participate with Sanwa on future drug development programs involving joint discoveries based on VistaGen's technology in the field of diabetes.
Financial terms of the agreement were not released.